Muhammad Ashfaq Khan’s Post

ACGT Research Fellows Nabil Ahmed, MD, and Meenakshi Hegde, MD (both of Baylor College of Medicine) led a phase 1 clinical trial using CAR T-cell therapy for advanced sarcoma. Drs. Ahmed and Hegde's CAR T cells target the HER2 protein, which is overexpressed on the surface of sarcoma cells. The HEROS 2.0 trial showed that this therapeutic approach is safe and associated with clinical benefit. One patient is cancer-free more than five years after treatment. Read more about the study: https://lnkd.in/d-V2G464

🧬 At this year’s American Liver Foundation's Arias Liver Symposium, our Founder and CSO, Quin Wills, presented 'Developing Cirrhosis Therapies: The Three Grand Challenges' – addressing some of the most critical hurdles in advanced liver disease. Liver disease continues to rise globally, with UK deaths increasing by nearly 60% over the past two decades. During his presentation, Quin shared Ochre’s strategies for tackling this urgent issue: 🔸 Using human-first data to create foundational datasets, like tissue atlases and gene perturbation studies, to uncover new therapeutic targets. 🔸 Model complexity vs scalability and balancing intricate human disease models with the need for scalability. 🔸 Rapid testing cycles and using technologies like RNA printing to refine potential therapies faster. 🔸 Advanced human models, like the organ perfusion systems at our New York Liver Lab, are bridging the gap to clinical trials. Missed the conference? Feel free to reach out with any questions or drop Quin a comment below!

Advanced GenAI and Single-Cell RNA-Seq Platform for Lung Fibrosis Drug Discovery The UCEHCA Lung Atlas is a comprehensive single-cell reference atlas of the human lung, integrating data from over 2 million cells across various lung tissues and diseases. This atlas employs GenAI, LLMs, and foundation models for semantic search and analysis at the single-cell level. These advanced tools enable precise identification and characterization of rare cell types and sub-cell types, particularly in idiopathic pulmonary fibrosis (IPF). By leveraging these technologies, researchers can uncover novel insights into disease mechanisms and identify potential therapeutic targets, significantly advancing GenAI-based drug discovery in lung fibrosis. The UCE (Universal Cell Embeddings, a foundation model for cell biology) pretrained (zero-shot) model has been tested and employed to identify key players in lung fibrosis and specific cell types, aiding in the discovery of therapeutic targets.

Fantastic work from Ravi Shah, Saumya Das and Perry et al. Proteomic and transcriptomic data linked to imaging phenotypes revealed early biomarkers of MASLD across diverse cohorts. Key pathways in metabolism, inflammation, and fibrosis were identified, including targets like EGFR, MET, and ALDOB. A liver-on-a-chip model highlighted cell-specific transcription and protein changes during steatosis progression. Findings were confirmed across spatial transcriptomics, single-cell analyses, and large-scale cohorts, supporting diagnostic and prognostic potential.

𝗔 𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗺𝗼𝗱𝗲𝗹 𝘀𝘆𝘀𝘁𝗲𝗺 𝗳𝗼𝗿 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗶𝗻 𝗳𝗮𝘁𝘁𝘆 𝗹𝗶𝘃𝗲𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲: Scientists from the Medical Faculty Mannheim, Heidelberg University have developed a model system that can be used to test the efficacy of drugs for fatty liver disease. It is a three-dimensional (3D) in vitro cell culture system based on primary human liver parenchymal cells (hepatocytes). The model system can help to identify novel target molecules for the treatment of fatty liver disease. It can also be used to develop treatment strategies that take into account differences in sex and ethnicity among patients. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eHXC3QVr Universität Heidelberg, Yun Kwon , Pascal Gottmann , Surui Wang , Joël Tissink  Karsten M. , Revathi Sekar, Ph.D. , Dr. rer. nat. Wiebke Albrecht , Cristina Cadenas, Annette Schürmann , Anja Zeigerer

Excited about the transformative potential of Liver-Chip technology in advancing research on MASLD! This study highlights how Liver-Chip replicates key features of human liver biology, validates biomarkers, and bridges clinical data with in vitro findings. Check out our publication: https://lnkd.in/eQ4aKpjx It’s always a pleasure collaborating with Emeli Chatterjee John FK Sauld Saumya Das Emulate, Inc. #MASLD #OrganChip #Emulate

🔎 ZOOM ON... GvHD models #GvHD is a significant complication of allogeneic transplants, characterized by an immune-mediated attack on the recipient's tissues by donor cells. At Oncodesign Services, we have developed GvHD models to: - understand the pathophysiology of GvHD, - test potential therapeutic interventions and - optimize treatment strategies, using a combination of in vitro and in vivo platforms. For more information, click here 👇 https://ow.ly/xoek50SjQrQ

New Discovery in ALS Therapy! We are excited to share pivotal preclinical data on NUZ-001, marking a crucial step in our journey to transform ALS treatment.    Highlights of Preclinical Findings: 💡 NUZ-001 and its active metabolite reduced TDP-43 protein aggregation, a hallmark feature of ALS pathology. 💡Treatment improved electrophysiological dysfunction of TDP-43 mutated M337V Motor Neurons. 💡 These results provide valuable insights into NUZ-001’s mechanism of action and reinforce the promising efficacy data seen in our Phase 1 MEND study earlier this year   This discovery solidifies our path forward as we prepare with confidence for the HEALEY ALS Platform Trial. We are one step closer to providing new hope for the ALS community.   👉 Learn more in the full press release at https://lnkd.in/eCyew6pv

🔬Citation Break!📖 This citation investigates the potential role of IGF-1 in Alzheimer's Disease and how it may contribute to neuroinflammation. Our Beta-Amyloid (1-42) NaOH (Cat# A-1165) was used in MTT assays with microglia cells, in Phagocytosis Assays, and ELISAs. We also offer FITC-conjugated BA 1-42 for those wishing to explore similar experiments using a fluorescent molecule. Paper: https://t.ly/9PjP8 Beta-Amyloid (1-42) NaOH: https://t.ly/wwyyQ #Research #Development #rPeptide #Experiments #BetaAmyloid #NaOH

📢 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐀-𝟒𝟗𝟖 𝐂𝐞𝐥𝐥𝐬: 𝐘𝐨𝐮𝐫 𝐌𝐨𝐝𝐞𝐥 𝐟𝐨𝐫 𝐑𝐞𝐧𝐚𝐥 𝐂𝐚𝐫𝐜𝐢𝐧𝐨𝐦𝐚 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 We provide a comprehensive overview of A-498 cells, a human renal carcinoma cell line crucial for tumor research. Derived from a 52-year-old female patient, these epithelial-like cells are perfect for transfection and studying renal cell carcinoma. Dive into our detailed guide covering cultivation conditions, passaging, cryopreservation steps, and common applications to jumpstart your experiments with ease. 🔬 𝐊𝐞𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: ◾ Cell Morphology: Adherent with epithelial-like features, clear boundaries at low density. ◾ Culture Conditions: Optimal growth at 37°C, 5% CO2, and 70-80% humidity. ◾ Passaging and Cryopreservation: Step-by-step protocols to maintain cell health and viability. ◾ Research Applications: Ideal for studying signaling pathways, drug effects, and creating animal models for renal carcinoma. 👉 Read the full article and enhance your research with A-498 cells today! 🔗 https://lnkd.in/ePUs_8EC #RenalCarcinoma #CellCulture #A498Cells #TumorResearch #CellBiology #CancerResearch #Transfection #Cryopreservation #LabProtocols #BiotechResearch #Pricella